ArticleFrontiers in endocrinology2025
Transcriptomics and network pharmacology reveal the potential mechanism related to integrated stress response in the treatment of osteoporosis by Jiawei Shentong Zhuyu Decoction and verified by RT-qPCR.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Osteoporosis (OP) is a systemic skeletal disorder. The molecular mechanisms underlying the effects of Jia Wei Shentong Zhuyu Decoction (JWSTZYD) and the integrated stress response (ISR) in OP remain unclear. This study aims to elucidate the mechanisms by which JWSTZYD and ISR contribute to OP. Methods: Potential drug target genes for JWSTZYD and OP-related datasets were sourced from the Gene Expression Omnibus (GEO) and Traditional Chinese Medicine Systems Pharmacology (TCMSP) databases. Differentially expressed genes (DEGs) in OP were identified by analyzing transcriptome data. Candidate genes were selected by intersecting target genes, DEGs, and ISR-related genes (ISR-RGs), with further screening based on expression levels in OP and control samples. The potential mechanisms of these biomarkers in OP were explored through gene set enrichment analysis (GSEA), immune infiltration analysis, molecular regulatory networks, and molecular docking. Expression levels of biomarkers were validated using clinical samples. Results: Conclusion: This study identified
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.